An interesting question seems to be whether the use of asprosin antibodies, apart from the effect of reducing food intake as a result of lowering the concentration of asprosin (as shown by [1]), could have the effect of reducing the severity of obesity-related inflammation. Here, FBN1 is linked to obesity due to melanocortin 4 receptor deficiency.